Cited by 82Cardiovascular Disease and AdiposityAtherosclerosis and Cardiovascular DiseasesAdipokines, Inflammation, and Metabolic Diseases

Chemerin and CMKLR1 expression in human arteries and periadventitial fat: a possible role for local chemerin in atherosclerosis?

Open access
Kostopoulos, Christos G, Spiroglou, Sofia G, Varakis, John N, Apostolakis, Efstratios, Papadaki, Helen H·2014·BMC Cardiovascular Disorders

Abstract

BACKGROUND: Depending on their anatomical location, different fat depots have a different capacity to produce bioactive peptides, called adipokines. Adipokines produced by periadventitial fat have been implicated in the pathogenesis of vascular disease, including atherosclerosis. Chemerin is an adipokine with an established role in immunity, adipose tissue function and metabolism, acting in autocrine, paracrine and endocrine manners. We investigated the protein expression of chemerin and its receptor, CMKLR1, in human aortas, coronary vessels and the respective periadventitial adipose tissue and correlated their expression with the presence of atherosclerosis. METHODS: Immunohistochemistry for chemerin and CMKLR1 was performed on human aortic and coronary artery samples including the periadventitial adipose tissue. Aortic and coronary atherosclerotic lesions were assessed using the AHA classification. RESULTS: Chemerin immunopositivity was noticed in both periadventitial fat depots, in vascular smooth muscle cells and foam cells in atherosclerotic lesions. Periadventitial fat and foam cell chemerin immunopositivity was statistically significantly correlated with the severity of atherosclerosis in both locations. CMKLR1 was expressed in vascular smooth muscle cells and foam cells in aortic and coronary vessels with atherosclerotic lesions. CMKLR1 immunostaining in foam cells was statistically significantly correlated with aortic atherosclerosis. CONCLUSIONS: Our results lend some support to a presumable role of locally produced chemerin in the progression of atherosclerotic lesions, possibly acting through its CMKLR1 receptor. Further research will elucidate the role of chemerin signaling in atherosclerosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2261-14-56

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ALX/FPR2 and ChemR23 are expressed in human aortic, coronary, and carotid atherosclerotic lesions, indicating that their pro-resolving ligands act locally within the vascular wall.

    “These receptors are expressed in human aortic, coronary and carotid atherosclerotic lesions104–106, indicating that their pro-resolving ligands exert local effects within the vascular wall (TABLE 1).”
  • Chemerin is a ChemR23 ligand present in human atherosclerotic lesions and correlates with disease severity.

    “The adipokine chemerin is another ChemR23 ligand116 that is present in human atherosclerotic lesions and correlates with disease severity106.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kostopoulos, C. G., Spiroglou, S. G., Varakis, J. N., Apostolakis, E., & Papadaki, H. H.
Affiliations
  • University of Patras (GR)
  • University of Ioannina (GR)
Corresponding author
Kostopoulos, Christos G
Venue
BMC Cardiovascular Disorders
Published
2014-04-30
Volume
14
Issue
1
Pages
56-56
ISSN
1471-2261 (ISSN-L)
OpenAlex
W1984836036
Cited by
82
References
31
Citations by year
2026: 2 · 2025: 7 · 2024: 7 · 2023: 9 · 2022: 4 · 2021: 9 · 2020: 10 · 2019: 10 · 2018: 6 · 2017: 6 · 2016: 5 · 2015: 4 · 2014: 2 · 2013: 1
FWCI
3.89
Type
journal article
Language
en
Open access
Locations
  • BMC Cardiovascular Disorders (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
University of Patras
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
chemerin, CMKLR1, atherosclerosis, adipokines, coronary arteries, aorta, foam cells, vascular smooth muscle cells, atherosclerotic lesion severity
MeSH terms
Adipose Tissue, Adolescent, Adult, Aged, Aged, 80 and over, Aorta, Abdominal, Aortic Diseases, Autopsy, Coronary Artery Disease, Coronary Vessels, Foam Cells, Humans, Immunohistochemistry, Middle Aged, Muscle, Smooth, Vascular, Disease Progression, Chemokines, Receptors, Chemokine, Intercellular Signaling Peptides and Proteins, Atherosclerosis, Young Adult, Adventitia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review